University of Alberta
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty
Phase 2
Terminated
- Conditions
- Rotator Cuff InjuriesAnesthesia; Functional
- Interventions
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 17
- Registration Number
- NCT04020601
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
The Impact of a Preoperative Nerve Block in Foot and Ankle Surgery on the Consumption of Sevoflurane
Phase 2
Withdrawn
- Conditions
- Anesthesia; FunctionalAnkle ArthropathyAnkle Arthritis
- Interventions
- Drug: Ropivacaine injectionDrug: Dextrose 5
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT04022057
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Phase 2
Withdrawn
- Conditions
- Liver DiseasesBowel DiseaseAnesthesia; FunctionalPancreas Disease
- Interventions
- Drug: Ropivacaine-SufentanilDrug: Dextrose 5
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT04021264
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
MRI Assessment of Pulmonary Edema in Acute Heart Failure
Recruiting
- Conditions
- Pulmonary Edema With Heart FailureAcute Heart Failure
- Interventions
- Diagnostic Test: MRI
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 300
- Registration Number
- NCT03999138
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry
Completed
- Conditions
- Sedative Adverse Reaction
- Interventions
- Combination Product: Propofol and Remifentanil administered by TCI pump
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 101
- Registration Number
- NCT03995134
- Locations
- 🇨🇦
Dr. Douglas Lobb, Edmonton, Alberta, Canada
🇳🇿Dr. Don Macalister, Auckland, New Zealand
Improving Children's Cooperation During Dental Injection
Not Applicable
Withdrawn
- Conditions
- Child BehaviorAcute Pain
- Interventions
- Behavioral: behavioral primingBehavioral: endowment effectBehavioral: Positive reinforcement
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT03978390
Syncope Trial to Understand Tilt Testing Early or Recorders Study
Not Applicable
Recruiting
- Conditions
- Syncope
- Interventions
- Diagnostic Test: Head Up Tilt Table (HUT)Device: Implantable Loop Recorder
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT03974412
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Systemic Effects of Lidocaine Infusion for TAP Block Catheter
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 80
- Registration Number
- NCT03971708
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Improving Hypertension Detection and Control Through a Hypertension Certification Program Based Upon the Hypertension Canada Guidelines
Not Applicable
Completed
- Conditions
- Hypertension
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 890
- Registration Number
- NCT03965104
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Combination Antiretroviral Therapy (cART) for PBC
Phase 2
Completed
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)Drug: Placebo Oral Capsule [CEBOCAP]Drug: Raltegravir
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 37
- Registration Number
- NCT03954327
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇨🇦University of Montreal, Montréal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath